Loading…
Homebuyer Assistance Act of 2021
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
66pct
12d open
vs 9,698 other HR bills in the 117th — cohort avg 63d
Homebuyer Assistance Act of 2021 This bill modifies requirements for appraisers of Federal Housing Administration-insured mortgages. Currently, an appraiser must be certified by certain state or national entities. The bill removes the national entities from the list of approved certification entities and allows an appraiser for a mortgage for single-family housing to be state-licensed rather than state-certified to meet requirements. The bill also provides specified educational requirements for appraisers for mortgages for single-family housing.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (5)
2023 · second_quarter · Health Issues
Received in the Senate and Read twice and referred to the Committee on Banking, Housing, and Urban Affairs.
Pursuant to section 5 of H. Res. 403, and the motion offered by Mr. Hoyer, the following bills passed under suspension of the rules: H.R. 144, as amended; H.R. 204, as amended; H.R. 210, as amended; H.R. 240; H.R. 707, as amended; H.R. 711, as amended; H.R. 1157, as amended; H.R. 1447, as amended; H.R. 1510, as amended; H.R. 1711, as amended; H.R. 2027; H.R. 2167, as amended; H.R. 2441; H.R. 2494; H.R. 2533; H.R. 2655, as amended; H.R. 2695, H.R. 2704; H.R. 2788; H.R. 2878, as amended; and H.R. 3008. (consideration: CR H2482-2520; text: CR H2519)
Passed/agreed to in House: Pursuant to section 5 of H. Res. 403, and the motion offered by Mr. Hoyer, the following bills passed under suspension of the rules: H.R. 144, as amended; H.R. 204, as amended; H.R. 210, as amended; H.R. 240; H.R. 707, as amended; H.R. 711, as amended; H.R. 1157, as amended; H.R. 1447, as amended; H.R. 1510, as amended; H.R. 1711, as amended; H.R. 2027; H.R. 2167, as amended; H.R. 2441; H.R. 2494; H.R. 2533; H.R. 2655, as amended; H.R. 2695, H.R. 2704; H.R. 2788; H.R. 2878, as amended; and H.R. 3008.(consideration: CR H2482-2520; text: CR H2519)
Pursuant to the provisions of H. Res. 403, proceedings on H.R. 3008 are considered vacated.
At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
DEBATE - The House proceeded with forty minutes of debate on H.R. 3008.
Bills with similar content found using semantic analysis.
Sources: Congress.gov
H.R. 198: Drug Pricing Transparency and Accountability Act - Provisions related to the 340B Program H.R. 830/ S. 1375: HELP Copays Act - To amend title XXVII of the Public Health Service Act to apply additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans, and for other purposes H.R. 1790: Biologics Competition Act of 2023 - To direct the Secretary of Health and Human Services to evaluate the extent to which the substitution of interchangeable biological products is impacted by differences between the system for determining a biological product to be interchangeable and the system for assigning therapeutic equivalence ratings to drugs, and for other purposes H.R. 2500: Protecting Americans from Unsafe Drugs Act of 2023 H.R. 2679: Pharmacy Benefit Manager Accountability Act H.R. 2816: Pharmacy Benefit Manager Sunshine and Accountability Act H.R. 2940/S 1355 PASTEUR Act/Incentives to increase novel antibiotic medicines H.R. 2880: Protecting Patients Against PBM Abuses Act H.R. 3008: Drug Shortage Prevention Act of 2023 H.R. 3281: Transparent PRICE Act H.R. 3285: Fairness for Patient Medications Act H.R. 3290: To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program/Transparency Legislation H.R. 3433: Give Kids a Chance Act of 2023 H.R. 3561: Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or PATIENT Act of 2023 H.R. 3791: Improving DATA in Public Health Act H.R. 3793: Ensuring Access to Lifesaving Drugs Act of 2023 H.R. 3810: Drug Origin Transparency Act of 2023 H.R. 4390: Protect 340B Act - Provisions related to 340B Program (117th Congress) H.R. 5376: Inflation Reduction Act of 2022 (P.L. 117-169)/Implementation of $0 Vaccine co-pay; maximum fair price provisions H.R. 7032: Increasing Transparency in Generic Drug Applications Act of 2022 - This bill requires the Food and Drug Administration to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why) (117th Congress) H.R. 7653: Modern Authentication of Pharmaceuticals Act of 2022 (117th Congress) S. 6: Biosimilar Red Tape Elimination Act (117th Congress) S. 113: Prescription Pricing for the People Act of 2023 - Provisions related to PBMs S. 127: Pharmacy Benefit Manager Transparency Act of 2023 - Provisions related to PBMs S. 148: Stop STALLING Act - Provisions related to citizen petitions S. 315: Taxpayer Research And Contributions Knowledge Act of 2023 or TRACK Act of 2023 - To direct the Secretary of Health and Human Services and other Federal officials to compile into a searchable database information relating to Federal support for biomedical research and development, and for other purposes. S. 476: Maintaining Investments in New Innovation Act S. 775: Increasing Transparency in Generic Drug Applications Act S. 1128: Ensuring Access to Generic Medications Act S. 898: Fair Accountability and Innovative Research Drug Pricing Act of 2021 - Provisions related to drug pricing (117th Congress) S. 1967: Patients Before Middlemen (PBM Act) S. 1067: Ensuring Timely Access to Generics Act of 2023 S. 1114: Expanding Access to Low-Cost Generics Act 2023 S. 1214: RARE Act - To set forth limitations on exclusive approval or licensure of drugs designated for rare diseases or conditions S. 1264: SMART Prices Act - Provisions related to drug pricing reform S. 1339: Pharmacy Benefit Manager Reform Act - Provisions related to PBMs S. 1355: PASTEUR Act of 2023 - Provisions related to antimicrobial resistance policy issues S. 1375: HELP Copays Act - To amend title XXVII of the Public Health Service Act to apply additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans, and for other purposes S. 1542: Delinking Revenue from Unfair Gouging Act or DRUG Act - Provisions related to PBMs S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics Act or PREVENT Pandemics Act (117th Congress) Pharmacy Benefit Manager reform and policy issues Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA) Cancer Moonshot Initiative 21st Century Cures 2.0 Drug cost and pricing policy issues Principles for drug pricing reform Drug importation policy issues Accelerated approval policy issues FDA regulatory approval authority policy issues Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance (AMR) policy issues Mental health policy issues High deductible health plans/HSA policy issues Supply chain policy issues Real world evidence policy issues Clinical trial diversity policy issues Prescription drug abuse policy issues 340B drug discount program policy issues Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues COVID-19 policy issues Pandemic preparedness policy issues Defense Production Act policy issues Cybersecurity policy issues Anticounterfeiting policy issues Chronic Kidney Disease Improvement in Research and Treatment Act. H.R.2534 - PROTECT 340B Act of 2023 House Draft Language for PAHPA Reauthorization HR 3665 - Defending American Jobs and Investment Act Senate Draft Language for PAHPA Reauthorization Pandemic and All Hazards Preparedness Act reauthorization (discussion draft) Labor HHS appropriations (ongoing discussion) Under Taxed Profit Rule, Ways and Means Committee discussion Vaccine Injury Compensation Program reform discussion
Client expense: $900,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2023 · second_quarter · Health Issues
H.R. 198: Drug Pricing Transparency and Accountability Act - Provisions related to the 340B Program H.R. 830: HELP Copays Act - To amend title XXVII of the Public Health Service Act to apply additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans, and for other purposes H.R. 1790: Biologics Competition Act of 2023 - To direct the Secretary of Health and Human Services to evaluate the extent to which the substitution of interchangeable biological products is impacted by differences between the system for determining a biological product to be interchangeable and the system for assigning therapeutic equivalence ratings to drugs, and for other purposes H.R. 2500: Protecting Americans from Unsafe Drugs Act of 2023 H.R. 2534: PROTECT 340B Act of 2023 - Provisions related to the 340B program H.R. 2679: Pharmacy Benefit Manager Accountability Act H.R. 2816: Pharmacy Benefit Manager Sunshine and Accountability Act H.R. 2880: Protecting Patients Against PBM Abuses Act H.R. 3008: Drug Shortage Prevention Act of 2023 H.R. 3281: Transparent PRICE Act H.R. 3285: Fairness for Patient Medications Act H.R. 3290: To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program H.R. 3433: Give Kids a Chance Act of 2023 H.R. 3561: Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or PATIENT Act of 2023 H.R. 3791: Improving DATA in Public Health Act H.R. 3793: Ensuring Access to Lifesaving Drugs Act of 2023 H.R. 3810: Drug Origin Transparency Act of 2023 H.R. 5376: Inflation Reduction Act of 2022 (P.L. 117-169) H.R. 7032: Increasing Transparency in Generic Drug Applications Act of 2022 (117th Congress) H.R. 7653: Modern Authentication of Pharmaceuticals Act of 2022 (117th Congress) S. 6: Biosimilar Red Tape Elimination Act (117th Congress) S. 113: Prescription Pricing for the People Act of 2023 - Provisions related to PBMs S. 127: Pharmacy Benefit Manager Transparency Act of 2023 - Provisions related to PBMs S. 148: Stop STALLING Act - Provisions related to citizen petitions S. 315: Taxpayer Research And Contributions Knowledge Act of 2023 or TRACK Act of 2023 - To direct the Secretary of Health and Human Services and other Federal officials to compile into a searchable database information relating to Federal support for biomedical research and development, and for other purposes S. 476: Maintaining Investments in New Innovation Act S. 775: Increasing Transparency in Generic Drug Applications Act S. 1128: Ensuring Access to Generic Medications Act S. 935: Fair Accountability and Innovative Research Drug Pricing Act of 2023 - Provisions related to drug pricing S. 1067: Ensuring Timely Access to Generics Act of 2023 S. 1114: Expanding Access to Low-Cost Generics Act 2023 S. 1214: RARE Act - To set forth limitations on exclusive approval or licensure of drugs designated for rare diseases or conditions S. 1264: SMART Prices Act - Provisions related to drug pricing reform S. 1339: Pharmacy Benefit Manager Reform Act - Provisions related to PBMs S. 1355: PASTEUR Act of 2023 - Provisions related to antimicrobial resistance policy issues S. 1375: HELP Copays Act - To amend title XXVII of the Public Health Service Act to apply additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans, and for other purposes S. 1542: Delinking Revenue from Unfair Gouging Act or DRUG Act - Provisions related to PBMs S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics Act or PREVENT Pandemics Act (117th Congress) Pharmacy Benefit Manager reform and policy issues Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA) Cancer Moonshot Initiative 21st Century Cures 2.0 Drug cost and pricing policy issues Principles for drug pricing reform Drug importation policy issues Accelerated approval policy issues FDA regulatory approval authority policy issues Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance (AMR) policy issues Mental health policy issues High deductible health plans/HSA policy issues Supply chain policy issues Real world evidence policy issues Clinical trial diversity policy issues Prescription drug abuse policy issues 340B drug discount program policy issues Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues COVID-19 policy issues Pandemic preparedness policy issues Defense Production Act policy issues Cybersecurity policy issues Anticounterfeiting policy issues
Client expense: $6,300,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
2022 · fourth_quarter · Financial Institutions/Investments/Securities
Monitoring legislation and regulation of residential housing industry, specifically related to valuations and appraisal regulatory reform. H.R. 3008, the Homebuyer Assistance Act of 2021. H.R. 2553, the Real Estate Valuation Fairness and Improvement Act of 2021; and appraisal related amendments to the National Defense Authorization Act.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Housing
Discussions involving housing finance reform legislation Monitored H.R.7735, Improving Access to the VA Home Loan Benefit Act of 2022 Monitored H.R.3008, Homebuyer Assistance Act of 2021 Monitored issues relating to implementation of P.L.116-136, CARES Act (Provisions related to mortgage forbearance for consumers and liquidity for mortgage servicers) Monitored executive branch nominations to federal agencies and commissions
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Housing
Discussions involving housing finance reform legislation Monitored H.R.7735, Improving Access to the VA Home Loan Benefit Act of 2022 Monitored H.R.3008, Homebuyer Assistance Act of 2021 Monitored issues relating to implementation of P.L.116-136, CARES Act (Provisions related to mortgage forbearance for consumers and liquidity for mortgage servicers) Monitored executive branch nominations to federal agencies and commissions
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Financial Institutions/Investments/Securities
Monitoring legislation and regulation of residential housing industry, specifically related to valuations and appraisal regulatory reform. H.R. 3008, the Homebuyer Assistance Act of 2021. H.R. 2553, the Real Estate Valuation Fairness and Improvement Act of 2021; and appraisal related amendments to the National Defense Authorization Act.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Financial Institutions/Investments/Securities
Monitoring legislation and regulation of residential housing industry, specifically related to valuations and appraisal regulatory reform. H.R. 3008, the Homebuyer Assistance Act of 2021. H.R. 2553, the Real Estate Valuation Fairness and Improvement Act of 2021.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Housing
Discussions involving housing finance reform legislation Monitored executive branch nominations to federal agencies and commissions Monitored H.R.2553, Real Estate Valuation Fairness and Improvement Act of 2021 Monitored H.R.3008, Homebuyer Assistance Act of 2021 Monitored H.R.4616, Adjustable Interest Rate (LIBOR) Act of 2021 Monitored issues relating to implementation of P.L.116-136, CARES Act (Provisions related to mortgage forbearance for consumers and liquidity for mortgage servicers) Monitored issues relating to conforming loan limits
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Housing
Discussions involving housing finance reform legislation Monitored executive branch nominations to federal agencies and commissions Monitored H.R.2553, Real Estate Valuation Fairness and Improvement Act of 2021 Monitored H.R.3008, Homebuyer Assistance Act of 2021 Monitored H.R.4616, Adjustable Interest Rate (LIBOR) Act of 2021 Monitored issues relating to implementation of P.L.116-136, CARES Act (Provisions related to mortgage forbearance for consumers and liquidity for mortgage servicers) Monitored issues relating to conforming loan limits
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Financial Institutions/Investments/Securities
Monitoring legislation and regulation of residential housing industry, specifically related to valuations and appraisal regulatory reform. H.R. 3008, the Homebuyer Assistance Act of 2021. H.R. 2553, the Real Estate Valuation Fairness and Improvement Act of 2021.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · fourth_quarter · Housing
Discussions involving housing finance reform legislation Discussions related to the monitoring of federal agency nominations Monitored H.R.2553, Real Estate Valuation Fairness and Improvement Act of 2021 Monitored H.R.3008, Homebuyer Assistance Act of 2021 Monitored H.R.4616, Adjustable Interest Rate (LIBOR) Act of 2021 Monitored issues relating to implementation of P.L.116-136, CARES Act (Provisions related to mortgage forbearance for consumers and liquidity for mortgage servicers) Monitored issues relating to conforming loan limits
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · fourth_quarter · Housing
H.R. 3008 Homebuyer Assistance Act of 2021 S. 2131 Improving FHA Support for Small-Dollar Mortgages Act of 2021 Fannie Mae and Freddie Mac Guarantee Fees Government Sponsored Enterprises Reform and Recapitalization GSEs: Reform, Recapitalization, PSPA Amendments, Climate Change Housing Finance Reform National Flood Insurance reauthorization Qualified Mortgage Rules TILA-RESPA Integrated Disclosures
Client expense: $1,230,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), Consumer Financial Protection Bureau (CFPB), Farm Credit Administration, Federal Accounting Standards Advisory Board (FASAB), Federal Deposit Insurance Corporation (FDIC), Federal Housing Finance Agency (FHFA), Federal Reserve System, HOUSE OF REPRESENTATIVES, Internal Revenue Service (IRS), Natl Credit Union Administration (NCUA), Office of the Comptroller of the Currency (OCC), SENATE, Small Business Administration (SBA), Treasury, Dept of, White House Office
2021 · fourth_quarter · Financial Institutions/Investments/Securities
Monitoring legislation and regulation of residential housing industry, specifically related to valuations and appraisal regulatory reform. H.R. 3008, the Homebuyer Assistance Act of 2021. H.R. 2553, the Real Estate Valuation Fairness and Improvement Act of 2021.
Client expense: Not reported · Firm income: $20,000
Government targets: Consumer Financial Protection Bureau (CFPB), HOUSE OF REPRESENTATIVES, Housing & Urban Development, Dept of (HUD), SENATE
2021 · third_quarter · Financial Institutions/Investments/Securities
Monitoring legislation and regulation of residential housing industry, specifically related to valuations and appraisal regulatory reform. H.R. 3008, the Homebuyer Assistance Act of 2021. H.R. 2553, the Real Estate Valuation Fairness and Improvement Act of 2021.
Client expense: Not reported · Firm income: $20,000
Government targets: Consumer Financial Protection Bureau (CFPB), HOUSE OF REPRESENTATIVES, Housing & Urban Development, Dept of (HUD), SENATE
2021 · third_quarter · Housing
Discussions involving housing finance reform legislation Monitored H.R.2553, Real Estate Valuation Fairness and Improvement Act of 2021 Monitored H.R.3008, Homebuyer Assistance Act of 2021 Monitored H.R.4616, Adjustable Interest Rate (LIBOR) Act of 2021 Monitored issues relating to implementation of P.L.116-136, CARES Act (Provisions related to mortgage forbearance for consumers and liquidity for mortgage servicers)
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · third_quarter · Housing
H.R. 3008 Homebuyer Assistance Act of 2021 H.R. 3323 Federal Home Loan Banks' Mission Implementation Act S. 1684 Federal Home Loan Banks' Mission Implementation Act S. 2131 Improving FHA Support for Small-Dollar Mortgages Act of 2021 Fannie Mae and Freddie Mac Guarantee Fees Government Sponsored Enterprises Reform and Recapitalization GSE Adverse Market Fee GSEs: Reform, Recapitalization, PSPA Amendments, Climate Change Housing Finance Reform National Flood Insurance reauthorization Qualified Mortgage Rules TILA-RESPA Integrated Disclosures
Client expense: $940,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Consumer Financial Protection Bureau (CFPB), Farm Credit Administration, Federal Deposit Insurance Corporation (FDIC), Federal Housing Finance Agency (FHFA), Federal Reserve System, HOUSE OF REPRESENTATIVES, Internal Revenue Service (IRS), Natl Credit Union Administration (NCUA), Office of the Comptroller of the Currency (OCC), SENATE, Small Business Administration (SBA), Treasury, Dept of
2021 · second_quarter · Financial Institutions/Investments/Securities
Monitoring legislation and regulation of residential housing industry, specifically related to valuations and appraisal regulatory reform. H.R. 3008, the Homebuyer Assistance Act of 2001. H.R. 2553, the Real Estate Valuation Fairness and Improvement Act of 2021.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · second_quarter · Housing
H.R. 3008 Homebuyer Assistance Act of 2021 H.R. 3323 Federal Home Loan Banks' Mission Implementation Act S. 524 A Bill to create a Homeowner Assistance Fund at the Department of Treasury S. 1684 Federal Home Loan Banks' Mission Implementation Act S. 2131 Improving FHA Support for Small-Dollar Mortgages Act of 2021 Fannie Mae and Freddie Mac Guarantee Fees Federal Home Loan Bank Membership Government Sponsored Enterprises Qualified Mortgage Patch Government Sponsored Enterprises Reform and Recapitalization GSE Adverse Market Fee GSEs: Reform, Recapitalization, PSPA Amendments, Climate Change Housing Finance Reform Mortgage and Rental Relief Options Under CARES Act National Flood Insurance reauthorization Qualified Mortgage Rules TILA-RESPA Integrated Disclosures
Client expense: $830,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Consumer Financial Protection Bureau (CFPB), Federal Deposit Insurance Corporation (FDIC), Federal Housing Finance Agency (FHFA), Federal Reserve System, HOUSE OF REPRESENTATIVES, Internal Revenue Service (IRS), Natl Credit Union Administration (NCUA), Office of the Comptroller of the Currency (OCC), SENATE, Small Business Administration (SBA), Treasury, Dept of
Considered under suspension of the rules. (consideration: CR H2458-2460; text: CR H2458-2459)
Mr. Cleaver moved to suspend the rules and pass the bill.
Referred to the House Committee on Financial Services.
Introduced in House
Congress.gov source codes: 1000, Intro-H